24 June 2024
24 June 2024
The trial's findings showed that all three mezagitamab doses enhanced platelet counts versus placebo.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
In our latest report, we have examined the business environment and trends that are going to shape the biopharmaceutical industry in the next 12 months. The industry’s optimism regarding growth in the next 12 months is on the rise, but still below the levels seen in 2022. Anti-obesity medications were identified as the emerging pharmaceutical industry trend to have the greatest impact in 2024. Oncology continues to dominate the therapy landscape in 2024, but metabolic disorders are set to register the highest growth.
In our latest report, we have examined the business environment and trends that are going to shape the biopharmaceutical industry in the next 12 months. The industry’s optimism regarding growth in the next 12 months is on the rise, but still below the levels seen in 2022. Anti-obesity medications were identified as the emerging pharmaceutical industry trend to have the greatest impact in 2024. Oncology continues to dominate the therapy landscape in 2024, but metabolic disorders are set to register the highest growth.
Give your business an edge with our leading industry insights.
